🏛️ Verified NIH Record • Updated 2026-08-25

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP (NCT06920004)

A Phase 3, Randomized, Double-Blinded, Double-Dummy Study Evaluating the Efficacy and Safety of Intravenous Empasiprubart Versus Intravenous Immunoglobulin in Adults With Chronic Inflammatory Demyelinating Polyneuropathy

🟢 Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: argenx

🩺 Plain-English Summary (8th-Grade Level)

The main purpose of this study is to compare empasiprubart and IVIg for treating people with CIDP. This study consists of a Part A where participants will either receive empasiprubart and a placebo resembling IVIg, or IVIg and a placebo resembling empasiprubart for 24 weeks (6 months). Following Part A, participants will enter Part B in which all participants will receive empasiprubart for 96 weeks (24 months). More information can be found here: https://clinicaltrials.argenx.com/emvigorate

Who can join: Review the eligibility criteria below.

Location: University of Alabama — Birmingham, Alabama

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (89 Sites)

Showing the first 25 of 89 sites.

  • University of Alabama — Birmingham, Alabama
  • Samir Macwan, M.D., Inc. — Rancho Mirage, California
  • Colorado Springs Neurological Associates — Colorado Springs, Colorado
  • MedStar Washington Hospital Center — Washington D.C., District of Columbia
  • Homestead Associates in Research Inc — Homestead, Florida
  • Visionary Investigators Network — Miami, Florida
  • University of South Florida — Tampa, Florida
  • Paradigm Health System — Slidell, Louisiana
  • Erlanger Health System — Columbia, Maryland
  • University of Michigan Hospital — Ann Arbor, Michigan
  • Perelman Center for Advanced Medicine — Philadelphia, Pennsylvania
  • Jefferson Health Honickman Center — Philadelphia, Pennsylvania
  • NeuroCarePlus — Houston, Texas
  • National Neuromuscular Research Institute — Irving, Texas
  • INECO Neurociencias Oroño — Rosario,
  • Universitätsklinikum AKH Wien — Vienna,
  • PSEG Centro de Pesquisa Clinica — São Paulo,
  • Hospital Universitario San Ignacio — Bogotá,
  • Hospital Alma Máter de Antioquia — Medellín,
  • Hospital Neurologico de Colombia Fundacion Ivan Jimenez - El Neurologico — Medellín,
  • Fakultni nemocnice Brno — Brno,
  • Astra Kliinik — Tallinn,
  • Tartu University Hospital — Tartu,
  • AP-HP - Hôpital de la Pitié Salpétrière — Paris, Paris
  • CHU de Bordeaux - Hôpital Pellegrin — Bordeaux,

📞 Contact the Study Coordinator

Phone: (857) 350-4834

Email: clinicaltrials@argenx.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Chronic Inflammatory Demyelinating Polyneuropathy

Explore by condition: All Chronic Inflammatory Demyelinating Polyneuropathy clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Contact the study coordinator using the phone/email above.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗